Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 24, 2024, for the registration of 33,080,598 shares of common stock. The registration statement includes a preliminary prospectus detailing the proposed sale of shares by selling stockholders from time to time after the effective date of the Registration Statement. The sale may occur on the Nasdaq Capital Market or through private transactions at fixed or negotiated prices. The company will not receive any proceeds from the sale of shares by the selling stockholders. The registration statement also outlines the rights and obligations of the selling stockholders, including the potential methods of sale, such as block trades, broker transactions, or directly to purchasers. Avenue Therapeutics, a specialty pharmaceutical company, has indicated that the registration is part of its efforts to satisfy certain registration rights granted to the selling stockholders. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI'.
Avenue Therapeutics, Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 24, 2024, for the registration of 33,080,598 shares of common stock. The registration statement includes a preliminary prospectus detailing the proposed sale of shares by selling stockholders from time to time after the effective date of the Registration Statement. The sale may occur on the Nasdaq Capital Market or through private transactions at fixed or negotiated prices. The company will not receive any proceeds from the sale of shares by the selling stockholders. The registration statement also outlines the rights and obligations of the selling stockholders, including the potential methods of sale, such as block trades, broker transactions, or directly to purchasers. Avenue Therapeutics, a specialty pharmaceutical company, has indicated that the registration is part of its efforts to satisfy certain registration rights granted to the selling stockholders. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI'.
Avenue Therapeutics, Inc.已于2024年1月24日向美国证券交易委员会（SEC）提交了S-3表格，要求注册33,080,598股普通股。注册声明包括初步招股说明书，详细说明了在注册声明生效之日后不时出售股东的提议。出售可以在纳斯达克资本市场上进行，也可以通过私人交易以固定或协议价格进行。该公司不会从出售股票的股东那里获得任何收益。注册声明还概述了出售股东的权利和义务，包括潜在的出售方式，例如大宗交易、经纪交易或直接向买方交易。专业制药公司Avenue Therapeutics表示，此次注册是其满足授予出售股东的某些注册权的努力的一部分。该公司的普通股在纳斯达克资本市场上市，股票代码为 “ATXI”。
Avenue Therapeutics, Inc.已于2024年1月24日向美国证券交易委员会（SEC）提交了S-3表格，要求注册33,080,598股普通股。注册声明包括初步招股说明书，详细说明了在注册声明生效之日后不时出售股东的提议。出售可以在纳斯达克资本市场上进行，也可以通过私人交易以固定或协议价格进行。该公司不会从出售股票的股东那里获得任何收益。注册声明还概述了出售股东的权利和义务，包括潜在的出售方式，例如大宗交易、经纪交易或直接向买方交易。专业制药公司Avenue Therapeutics表示，此次注册是其满足授予出售股东的某些注册权的努力的一部分。该公司的普通股在纳斯达克资本市场上市，股票代码为 “ATXI”。
有用
没用